Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;20(1):6-7.
doi: 10.1038/s41423-022-00953-3. Epub 2022 Nov 15.

Cancer cells escape the immune system by increasing stemness through epigenetic reprogramming

Jose A Costoya  1 , Victor M Arce  2
Affiliations

Cancer cells escape the immune system by increasing stemness through epigenetic reprogramming

Jose A Costoya et al. Cell Mol Immunol. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Horizontal transfer of IFN-I-induced stemness in cancer. Dying tumor cells release extracellular vesicles (EVs) containing nucleic acids that are incorporated by neighboring viable cancer cells. EV cargos act as DAMPs in these cells, inducing further release of IFN-I that contributes to the stimulation of KDM1B transcriptional activity, which results in extensive chromatin reprogramming and subsequent induction of stemness. The final outcome of the process is the generation of novel populations of CSCs that will lead to boosted tumor resistance and increased relapse frequency. Created with BioRender.com
See this image and copyright information in PMC

References

    1. Bajaj J, Diaz E, Reya T. Stem cells in cancer initiation and progression. J Cell Biol. 2020;219:e201911053. doi: 10.1083/jcb.201911053. - DOI - PMC - PubMed
    1. Lei MML, Lee TKW. Cancer stem cells: emerging key players in immune evasion of cancers. Front Cell Dev Biol. 2021;9:692940. doi: 10.3389/fcell.2021.692940. - DOI - PMC - PubMed
    1. Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, et al. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol. 2022;23:1379–92. doi: 10.1038/s41590-022-01290-3. - DOI - PMC - PubMed
    1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi: 10.1146/annurev-immunol-032712-100008. - DOI - PubMed
    1. Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14:2994–3006. doi: 10.1002/1878-0261.12851. - DOI - PMC - PubMed

Publication types